Lowering platelet count threshold to 10,000/µL for peripherally inserted central catheter placement safely conserves blood products
- PMID: 35763062
- DOI: 10.1007/s00277-022-04891-y
Lowering platelet count threshold to 10,000/µL for peripherally inserted central catheter placement safely conserves blood products
Abstract
Despite the low risk of peripherally inserted central catheter (PICC) insertion-related bleeding, the practice of administering prophylactic platelets varies greatly. Limiting unnecessary blood product transfusions reduces transfusion-related adverse events, financial cost, and delays in care. We assessed the impact of lowering prophylactic platelet administration threshold on blood product utilization patterns and bleeding events. This quasi-experimental study was conducted in an urban academic tertiary medical center. The study population included patients with platelet counts ≥ 10,000/µL and < 50,000/µL undergoing PICC placement in 2018 and 2019 when the minimum platelet thresholds were 50,000/µL and 10,000/µL, respectively. The primary outcome was blood product utilization and the secondary outcome was PICC insertion-related bleeding complications. Thirty-five patients using the 10,000/µL (10 K) platelet threshold and 46 patients using the 50,000/µL (50 K) platelet threshold were enrolled. The 50 K group received more platelets before PICC insertion (0.870 ± 0.885 and 0.143 ± 0.430 pools of platelets-per-person, p < 0.001). No patients experienced clinically significant bleeding. Immediately following PICC insertion, minor bleeding occurred in five patients (two [4.3%] and three [8.6%] in the 50 K and 10 K groups, respectively). Bleeding rates between the two cohorts did not differ (p = 0.647). Lowering the minimum platelet threshold from 50,000/µL to 10,000/µL resulted in less prophylactic platelet and total blood product administration with no appreciable difference in PICC insertion-related bleeding.
Keywords: Bleeding; Blood-products; Central venous access; Procedure complications; Thrombocytopenia.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
References
-
- Kaufman RM, Djulbegovic B, Gernsheimer T et al (2015) Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162(3):205–213. https://doi.org/10.7326/M14-1589 - DOI - PubMed
-
- Schiffer CA, Bohlke K, Delaney M et al (2018) Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 36(3):283–299. https://doi.org/10.1200/JCO.2017.76.1734 - DOI - PubMed
-
- Patel IJ, Rahim S, Davidson JC et al (2019) Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 30(8):1168-1184.e1. https://doi.org/10.1016/j.jvir.2019.04.017 - DOI - PubMed
-
- Cavanna L, Citterio C, Nunzio Camilla D, Orlandi E, Toscani I, Ambroggi M (2020) Central venous catheterization in cancer patients with severe thrombocytopenia: ultrasound-guide improves safety avoiding prophylactic platelet transfusion. Mol Clin Oncol 12(5):435–439. https://doi.org/10.3892/mco.2020.2010 - DOI - PubMed - PMC
-
- AlRstum ZA, Huynh TT, Huang SY, Pisimisis GT (2019) Risk of bleeding after ultrasound-guided jugular central venous catheter insertion in severely thrombocytopenic oncologic patients. Am J Surg 217(1):133–137. https://doi.org/10.1016/j.amjsurg.2018.06.019 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
